Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 25
- Public Markets
Cannabis Stocks Hit Highest Point This Year on Trump Rescheduling Hopes
Cannabis stocks across North America have skyrocketed to their highest point so far this year, despite a lukewarm promise from the US President on cannabis rescheduling.
- Uncategorized
Deutschlands Medizinmarkt setzt angesichts der drohenden Verschärfungen sein Rekordwachstum fort
Das rasante Wachstum des deutschen Marktes für medizinisches Cannabis zeigte auch im zweiten Quartal 2025 keine Anzeichen eines Sinkflugs, wobei die Importe um weitere 15 % stiegen und neue Rekorde erreichten.
- Uncategorized
‘GMP Is the Foundation of Trust in Our Industry’ – Inside Linnea’s Take on Pharma-Grade Cannabinoids
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
- Public Markets
A Tale of Two Markets: German Cannabis Companies Chase Records as UK Operators Seek Exits
As Q2 2025 figures continue to roll in, the stark contrast between companies operating in the UK and Germany are becoming increasingly apparent.
- US & Canada
Cannabis Groundhog Day: Trump’s Rescheduling Talk Fuels Familiar Hype Cycle
The cannabis industry is once again awash with hope and speculation over the promise of rescheduling following reports that President Trump has promised the industry that ‘it’s something we’re going to look at’.
- Legal Analysis
Germany’s Medical Market Continues Record Growth in the Face of Clampdown
The blistering growth of Germany’s medical cannabis sector showed no signs of abating through the second quarter of 2025, with imports rising another 15% to hit new records.
- Medical Cannabis
Glass Pharms Signs Supply Agreement With CB1 Pharmacy Offering 3 New Affordable UK-Grown Strains
Glass Pharms has today announced a new supply deal set to see a new line of affordable, entirely UK-produced products enter the market.
- Investment & Finance
New Data, New Players: Why Cannabis Pharma Deserves Investor Attention
Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
- Hemp Industry
‘Huge Win’ for US Hemp Industry as Senate Removes Hemp-Killing Language from Funding Bill
In a major win for the US hemp industry, language which could have seen ‘90-95%’ of hemp products banned has been removed from a major US agricultural funding bill.
- Medical Cannabis
Why France’s Strict Medical Cannabis Plans Could be its Secret Weapon
Augur Associates and Newsweed, two organisations at the forefront of the ongoing developments in the region, believe that the incoming system not only sidesteps many of the issues other countries have faced in the implementation phase, but that it could reestablish the country’s standing as a model of inspiration for neighbouring states and prospective forthcoming EU supra-regulation.
- Medical Cannabis
Not on Our Watch: Releaf Pushes Back Against Rushed Cannabis Prescribing
The British Medical Association (BMA), which represents tens of thousands of General Practitioners in the UK, this week threatened new strike action amid increasing tensions with the Starmer government.
- Retail & Brands
New York Cannabis Regulator’s ‘Catastrophic’ Blunder Threatens Over 100 Businesses
Over 100 legal New York cannabis dispensaries could be forced to relocate following a monumental blunder from the state’s Office of Cannabis Management (OCM).
